Continuous glucose monitoring in high-risk subjects for developing type 2 diabetes

被引:2
作者
Costa, Bernardo [1 ]
Vizcaino, Jesus [1 ]
Cabre, Joan Josep [1 ]
Fuentes, Cruz Maria [1 ]
Boj, Joan [1 ]
Pinol, Josep Lluis [1 ]
机构
[1] Inst Catala Salut, Unidad Invest Diabet & Metab, Atenc Primaria Reus Tarragona, Tarragona, Spain
来源
MEDICINA CLINICA | 2006年 / 127卷 / 02期
关键词
diabetes; prediabetes; continuous glucose monitoring; impaired glucose tolerance; impaired fasting glucose;
D O I
10.1157/13089989
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND AND OBJECTIVE: To assess the relevance of unrecognised hyperglycaemia among high-risk subjects for developing type 2 diabetes. SUBJECTS AND METHOD: Cross-sectional multicentre study in primary care. Subjects aged 40 to 75 years with previous evidence of impaired glucose metabolism were screened according to the Word Health Organization rules by means of an oral glucose tolerance test (OGTT). Those with diabetes diagnostic criteria were excluded. An individualized 48-h ambulatory continuous glucose monitoring (CGM) calibrated by plasma values (Glucoday((R))) was performed. Data from biosensor activity were computerized in order to identify hyperglycaemic records. RESULTS: 50 out of 64 screened subjects were included and evaluated; there were 30 female (60%). Mean age was 59 years; body mass index, 30.9; HbA(1c), 5.3%, and HOMA, 2.8. Regarding the CGM results, 9 whole registers (18%) were rejected because of technical problems and 41 continuous profiles (72%) were analysed, corresponding to 17 (41.5%) subjects with normal OGTT and 24 (58.5%) with non-diabetic hyperglycaemia on OGTT. Mean CGM time with hyperglycaemia (fasting >= 6.1 mmol/l or non-fasting >= 7.8 mmol/l) accounted for 5.8 h, a 17.2% of the effective register per subject (33.8 h). Both groups matched the World Health Organization diabetes diagnostic interval (fasting >= 7 mmol/l or non-fasting >= 11.1 lmol/1): 1.1 h of effective register (3.6%) and 1.2 h (3.3%), respectively. CONCLUSIONS: The CGM evidenced a high degree of unrecognised hyperglycaemia among high-risk individuals. Therefore, casual plasma glucose measurements should be recommended to achieve early screening.
引用
收藏
页码:50 / 52
页数:3
相关论文
共 10 条
  • [1] Amer Diabet Assoc, 2005, DIABETES CARE, V28, pS37
  • [2] Costa B, 2005, Aten Primaria, V35, P99, DOI 10.1157/13071917
  • [3] Significant incidence of type 2 diabetes on high-risk Spanish population.: The IGT Study (2)
    Costa, B
    Piñol, JL
    Martín, F
    Donado, A
    Castell, C
    [J]. MEDICINA CLINICA, 2002, 118 (08): : 287 - 293
  • [4] Hypoglycaemia after pancreas transplantation:: usefulness of a continuous glucose monitoring system
    Esmatjes, E
    Flores, L
    Vidal, M
    Rodriguez, L
    Cortés, A
    Almirall, L
    Ricart, MJ
    Gomis, R
    [J]. CLINICAL TRANSPLANTATION, 2003, 17 (06) : 534 - 538
  • [5] Asymptomatic glycemic instability: how to measure it and which clinical applications?
    Guerci, B
    [J]. DIABETES & METABOLISM, 2003, 29 (02) : 179 - 188
  • [6] Continuous subcutaneous glucose monitoring in diabetic patients - A multicenter analysis
    Maran, A
    Crepaldi, C
    Tiengo, A
    Grassi, G
    Vitali, E
    Pagano, G
    Bistoni, S
    Calabrese, G
    Santeusanio, F
    Leonetti, F
    Ribaudo, M
    Di Mario, U
    Annuzzi, G
    Genovese, S
    Riccardi, G
    Previti, M
    Cucinotta, D
    Giorgino, F
    Bellomo, A
    Giorgino, R
    Poscia, A
    Varalli, M
    [J]. DIABETES CARE, 2002, 25 (02) : 347 - 352
  • [7] A novel continuous subcutaneous lactate monitoring system
    Poscia, A
    Messeri, D
    Moscone, D
    Ricci, F
    Valgimigli, F
    [J]. BIOSENSORS & BIOELECTRONICS, 2005, 20 (11) : 2244 - 2250
  • [8] The glucose area under the profiles obtained with continuous glucose monitoring system relationships with NbAlc in pediatric type-1 diabetic patients
    Salardi, S
    Zucchini, S
    Santoni, R
    Ragni, L
    Gualandi, S
    Cicognani, A
    Cacciari, E
    [J]. DIABETES CARE, 2002, 25 (10) : 1840 - 1844
  • [9] A microdialysis technique for continuous subcutaneous glucose monitoring in diabetic patients (part 2)
    Varalli, M
    Marelli, G
    Maran, A
    Bistoni, S
    Luzzana, M
    Cremonesi, P
    Caramenti, G
    Valgimigli, F
    Poscia, A
    [J]. BIOSENSORS & BIOELECTRONICS, 2003, 18 (07) : 899 - 905
  • [10] World Health Organization, 1999, REP WHO CONS DEF DIA